Evaluation of supportive and barrier-protective skin care products in the daily prevention and treatment of cutaneous toxicity during systemic chemotherapy

Diana Lüftner,1 Veronica Dell’Acqua,2 Frédéric Selle,3 Ahmed Khalil,3 Maria Cristina Leonardi,2 Alejandro De La Torre Tomás,4 George Shenouda,5 Jesus Romero Fernandez,4 Roberto Orecchia,2,6 Dominique Moyal,7 Sophie Seité7 1Department of Hematology, Oncology and Tumor Immunology, Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; 2Department of Radiotherapy, IEO, European Institute of Oncology IRCCS, Milan, Italy; 3Tenon Hospital, Paris, France; 4Puerta de Hierro Hospital, Madrid, Spain; 5McGill Hospital, Montreal, Canada; 6Milan University, Milan, Italy; 7La Roche-Posay Dermatological Laboratory, Levallois-Perret, France Introduction: The purpose of this multicenter, prospective, observational, open-label study was to evaluate the use and tolerability of dermo-cosmetic products in preventing skin reactions associated with cancer treatments. Patients and methods: A 12-product kit was supplied to patients before chemotherapy began and was to be used throughout the treatment phase. Cutaneous adverse events were evaluated at each treatment session. Physicians evaluated skin reactions (edema, erythema, dryness, desquamation, pigmentation disorders, and cracks) and gave their opinion on the skin benefit for patients at the end of the study. Patients also evaluated the product benefit using the Patient Benefit Index (PBI) questionnaire. Results were analyzed by subgroups of casual and regular users, based on number and frequency of products used. Results: A total of 147 patients were enrolled in cancer services in Germany, France, Italy, Spain, and Canada. Mean age was 59 years with 71% being female. Product tolerance on whole body was rated good to excellent for at least 89% of the patients for each product. Aggravated skin reactions during the study were reported more frequently by casual users than regular users (39.5% versus 22%; p=0.029). Similarly, casual users reported more erythema aggravation (p=0.02) and desquamation (p=0.03) than regular users. PBI >1 was reported for 95.5% of patients and regular users had significantly higher scores than casual users (p=0.049). Discussion: Overall, the 12-product kit was very well tolerated, with regular users reporting benefits more frequently than casual users. Results support international recommendations to use appropriate skin care products to minimize the impact of cutaneous reactions associated with chemotherapy. Keywords: dermocosmetic, dermatological toxicity, skin side effect, skin reaction, palliative care